Subscribe
Copied to clipboard
Share
Share
Copied to clipboard
Embed
Copied to clipboard
Blood Cancer Talks
Trailer
Bonus
Episode 14
Season 1
Episode 13. Management of Newly Diagnosed Younger Adults with AML
January 11, 2023
Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
Full Transcript
View the website
Study showing the time from diagnosis of AML to the start of intensive treatment indicate that a treatment delay has no negative prognostic impact. https://ashpublications.org/blood/article/136/7/823/460669/Does-time-from-diagnosis-to-treatment-affect-the
RATIFY clinical trial showing the addition of midostaurin (FLT3 inhibitor) to 7+3 chemotherapy for AML https://www.nejm.org/doi/full/10.1056/nejmoa1614359
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the European LeukemiaNet (ELN) https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022
ASH 2022 abstract presenting Daunorubicin 60 Vs 90 mg/m2 https://ash.confex.com/ash/2022/webprogram/Paper157126.html
ALFA-0701. The addition of gemtuzumab ozogamicin, an anti-CD33 antibody conjugate, to the standard treatment for patients with acute myeloid leukemia
Quizartinib data presented at EHA 2022
International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemias
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission